Emicizumab
Phase 3CompletedDevelopment Stage
Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor
Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Hemophilia A
Feb 10, 2020 → Dec 19, 2025
About Emicizumab
Emicizumab is a phase 3 stage product being developed by Roche for Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor. The current trial status is completed. This product is registered under clinical trial identifier NCT04158648. Target conditions include Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Hemophilia A.
What happened to similar drugs?
8 of 16 similar drugs in Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor were approved
Hype Score Breakdown
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05181618 | Approved | Active |
| NCT04431726 | Phase 3 | Active |
| NCT04158648 | Phase 3 | Completed |
| NCT03315455 | Phase 3 | Completed |
| NCT03380780 | Phase 1 | Completed |
| NCT03191799 | Phase 3 | Completed |
Competing Products
20 competing products in Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor